Insights

Race (ASX:RAC) share price falters despite positive update

The Race Oncology (ASX:RAC) share price is struggling in early trade despite the company releasing a positive update. Let’s take a look.
The post Race (ASX:RAC) share price falters despite positive update appeared first on The Motley Fool Australia. –

falling asx share price represented by woman making sad face

The Race Oncology Ltd (ASX: RAC) share price is struggling in early-morning trade despite the company announcing the initiation of an extramedullary AML preclinical study. At the time of writing, the specialty pharmaceutical company’s shares are trading flat at $3.84 after falling by around 2% in earlier trade.

What did Race announce?

Investors appear unfazed by the company’s latest announcement, leaving the Race share price currently unchanged.

According to this morning’s release, Race has entered into a collaborative preclinical research program with The University of Newcastle. This partnership agreement aims to support the use of Bisantrene in the treatment of extramedullary acute myeloid leukaemia (AML).

Extramedullary AML is considered to be a rare and serious illness with about a 25% survival rate over a 5-year term. The life-threatening disease occurs when the leukaemia spreads from the bone marrow and forms solid tumours in tissues such as the skin, breast, kidney, brain, or other organs.

Race noted that a prospective positron imaging trial conducted in 2020 identified up to 22% of AML patients having extramedullary AML.

Furthermore, a recent phase 2 clinical trial undertaken at the Sheba Medical Centre found Bisantrene to be highly-effective in subjects with extramedullary AML. This is particularly pleasing for the company as there are limited treatment options available.

Once data is collated, Race will seek to move into a phase 2/3 trial of Bisantrene in extramedullary AML patients. It hopes that the United States Food and Drug Administration (FDA) will push ahead with a rapid pathway for approval of Bisantrene as an orphan drug.

Race chief scientific officer Dr Daniel Tillett commented:

This is a key project for Race using Associate Professor Verrills’ extramedullary AML mouse model. Recent clinical evidence has identified Bisantrene as an effective treatment option for patients with the difficult-to-treat extramedullary form of AML.

We believe that we have identified a low-risk pathway to rapid approval of Bisantrene via this indication that offers significant upside for Race in a crowded clinical space.

About the Race share price

The Race share price has gained over 1,500% in the past 12 months and is up by almost 100% year to date. It’s worth noting that the company’s shares reached an all-time high of $4.23 earlier this month.

Based on the current share price, Race commands a market capitalisation of around $531 million, with 138.4 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Race (ASX:RAC) share price falters despite positive update appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!